Bristol-Myers Squibb Company (BMY) Stock Analysis 2026

This chart shows how BMY's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Bristol-Myers Squibb Company trades at a trailing P/E of 14.67x, generates $8.11B in free cash flow, runs a debt/equity ratio of 201.86, and converts shareholder equity into profit at a 46.6% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

22 analysts covering Bristol-Myers Squibb Company currently lean toward a Hold rating, with a mean 12-month price target of $66.21 (+5.4% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

We use 1 valuation model to estimate BMY's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

BMY is currently in a golden cross pattern, trading above its 50-day average of $61.92 and above its 200-day average of $57.75. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.